Vast market for glaucoma pharmaceuticals, as 50% of patients remain untreated, finds F&S

Glaucoma is the second leading cause of blindness in the USA, presenting the glaucoma pharmaceuticals market with a significant opportunity to fulfill unmet medical needs. Being an adult disease, the patient pool for glaucoma will expand as the population ages.

A new analysis from Frost & Sullivan, titled Analysis of the United States Glaucoma Pharmaceuticals Market, finds that the market earned revenues of around $2.19 billion in 2010 and estimates this to reach $2.25 billion in 2016.

Considering almost 50% of the patient population is under-diagnosed and underserved with available pharmacotherapy options, pharmaceuticals that offer effective therapies, improved drug delivery, and higher disease awareness through patient education will be immensely successful. Additionally, patients suffering from glaucoma, whether they are aware of the disease or not, need therapies better than the numerous pharmacotherapy options available currently.